Raffles Medical Could Sustain Earnings Momentum Over 2026-2027 -- Market Talk

Dow Jones

01/23

0211 GMT - Raffles Medical Group likely returned to earnings growth in 2H last year and could sustain the momentum into 2026-2027, says RHB Research's Shekhar Jaiswal in a note. The analyst expects mid-teens expansion over the next two years, driven by a recovery in its Singapore hospitals, easing drag from its China business and stronger insurance profit. He projects 2026 and 2027 core profit to grow 14% and 17%, respectively. The Singapore healthcare company's stock is likely to benefit from share buybacks and its inclusion in the iEdge Next 50 index, which tracks the largest 50 companies outside the benchmark FTSE Straits Times Index. RHB Research maintains its buy rating and S$1.15 target price. Shares are flat at S$1.01.(megan.cheah@wsj.com)

(END) Dow Jones Newswires

January 22, 2026 21:11 ET (02:11 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2605413442"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2605413442\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2605413442?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-23 10:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605413442","market":"fut","top_or_hot":-1,"title":"Raffles Medical Could Sustain Earnings Momentum Over 2026-2027 -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0211 GMT - Raffles Medical Group likely returned to earnings growth in 2H last year and could sustain the momentum into 2026-2027, says RHB Research's Shekhar Jaiswal in a note. The analyst expects mid-teens expansion over the next two years, driven by a recovery in its Singapore hospitals, easing drag from its China business and stronger insurance profit. He projects 2026 and 2027 core profit to grow 14% and 17%, respectively. The Singapore healthcare company's stock is likely to benefit from share buybacks and its inclusion in the iEdge Next 50 index, which tracks the largest 50 companies outside the benchmark FTSE Straits Times Index. RHB Research maintains its buy rating and S$1.15 target price. Shares are flat at S$1.01.(megan.cheah@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 22, 2026 21:11 ET (02:11 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Raffles Medical Could Sustain Earnings Momentum Over 2026-2027 -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRaffles Medical Could Sustain Earnings Momentum Over 2026-2027 -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-01-23 10:11</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0211 GMT - Raffles Medical Group likely returned to earnings growth in 2H last year and could sustain the momentum into 2026-2027, says RHB Research's Shekhar Jaiswal in a note. The analyst expects mid-teens expansion over the next two years, driven by a recovery in its Singapore hospitals, easing drag from its China business and stronger insurance profit. He projects 2026 and 2027 core profit to grow 14% and 17%, respectively. The Singapore healthcare company's stock is likely to benefit from share buybacks and its inclusion in the iEdge Next 50 index, which tracks the largest 50 companies outside the benchmark FTSE Straits Times Index. RHB Research maintains its buy rating and S$1.15 target price. Shares are flat at S$1.01.(megan.cheah@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 22, 2026 21:11 ET (02:11 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BSL.SI","symbol_name":"萊佛士醫療","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2605413442","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2605413442","pubTimestamp":1769134260,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0211 GMT - Raffles Medical Group likely returned to earnings growth in 2H last year and could sustain the momentum into 2026-2027, says RHB Research's Shekhar Jaiswal in a note. The analyst expects mid-teens expansion over the next two years, driven by a recovery in its Singapore hospitals, easing drag from its China business and stronger insurance profit. He projects 2026 and 2027 core profit to grow 14% and 17%, respectively. The Singapore healthcare company's stock is likely to benefit from share buybacks and its inclusion in the iEdge Next 50 index, which tracks the largest 50 companies outside the benchmark FTSE Straits Times Index. RHB Research maintains its buy rating and S$1.15 target price. Shares are flat at S$1.01.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"BSL.SI":"莱佛士医疗"},"translate_title":"莱佛士医疗可能在2026-2027年维持盈利势头——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BSL.SI":1.5},"content_text":"0211 GMT - Raffles Medical Group likely returned to earnings growth in 2H last year and could sustain the momentum into 2026-2027, says RHB Research's Shekhar Jaiswal in a note. The analyst expects mid-teens expansion over the next two years, driven by a recovery in its Singapore hospitals, easing drag from its China business and stronger insurance profit. He projects 2026 and 2027 core profit to grow 14% and 17%, respectively. The Singapore healthcare company's stock is likely to benefit from share buybacks and its inclusion in the iEdge Next 50 index, which tracks the largest 50 companies outside the benchmark FTSE Straits Times Index. RHB Research maintains its buy rating and S$1.15 target price. Shares are flat at S$1.01.(megan.cheah@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 22, 2026 21:11 ET (02:11 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}